(Q46261812)

20 December 2017

title

Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions (English)

1 reference

20 December 2017

1 reference

11

1 reference

20 December 2017

author name string

J Score

1

1 reference

20 December 2017

C Walz

2

1 reference

20 December 2017

J V Jovanovic

3

1 reference

20 December 2017

A V Jones

4

1 reference

20 December 2017

K Waghorn

5

1 reference

20 December 2017

C Hidalgo-Curtis

6

1 reference

20 December 2017

F Lin

7

1 reference

20 December 2017

D Grimwade

8

1 reference

20 December 2017

F Grand

9

1 reference

20 December 2017

A Reiter

10

1 reference

20 December 2017

publication date

6 November 2008

1 reference

20 December 2017

published in

Leukemia

1 reference

20 December 2017

volume

23

1 reference

20 December 2017

issue

2

1 reference

20 December 2017

page(s)

332-339

1 reference

20 December 2017

https://scigraph.springernature.com/pub.10.1038/leu.2008.309

exact match

0 references

cites work

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

The eosinophilias, including the idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Treatment of patients with the hypereosinophilic syndrome with mepolizumab

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Chimeric LNA/DNA probes as a detection system for real-time PCR.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Detection and quantitation of neoplastic cells in acute lymphoblastic leukaemia, by use of the polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Amplification of human minisatellites by the polymerase chain reaction: towards DNA fingerprinting of single cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Imatinib for systemic mast-cell disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.309

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.309

1 reference

20 December 2017

1 reference

20 December 2017